密歇根大学健康中心的研究人员 Eric D. Smith 和 Venkatesh L. Murthy 于2026年11月3日在《JAMA Internal Medicine》发表观点文章,探讨了利用基因编辑技术治疗高胆固醇、心脏病等常见疾病的潜力及其伴随的重大风险 1。尽管单次基因干预理论上可能取代患者终身的药物治疗需求,但永久性基因改变所引发的长期安全隐患、复杂的监测难题以及高昂的治疗费用,构成了该技术广泛推广前的主要障碍 1。研究指出,虽然目前已识别出超过6000种罕见遗传病,但仅有少数具备明确的治疗靶点;此外,部分现有基因疗法的定价超过100万美元,若将其应用于数百万患者群体,将给医疗系统带来巨大的财务压力 1。
针对如何评估基因组干预的适用性,研究人员提出了五个关键考量因素:疾病严重程度、现有治疗方法、治疗持久性、递送风险和长期监测 1。在具体技术层面,许多基因疗法使用修饰病毒作为载体,免疫系统可能产生反应,导致难以重复给药 1。值得注意的是,当前基因疗法主要靶向体细胞,而非生殖系编辑,因此不会遗传给后代 1。研究者强调,在广泛推广前必须建立可靠的长期安全监控体系并解决可及性问题 1。
Researchers at the University of Michigan Health have published a perspective article in JAMA Internal Medicine examining the potential for gene editing to treat common conditions such as high cholesterol and heart disease. 1 While a single gene therapy session could theoretically eliminate the need for lifelong medication, the authors highlight significant challenges regarding long-term safety, monitoring difficulties, and prohibitive costs. 1 The study was authored by Eric D. Smith and Venkatesh L. Murthy and appeared on November 3, 2026. 1
The article notes that although over 6,000 rare genetic diseases have been identified, only a small fraction currently have available therapeutic targets. 1 For those treatments that do exist, some are priced at more than $1 million per patient, creating immense financial strain if scaled to millions of individuals with common ailments. 1 Additionally, many current gene therapies utilize modified viruses as delivery vectors, which can trigger immune responses that make repeat dosing difficult or impossible. 1 It is important to note that these interventions primarily target somatic cells rather than germline cells, meaning the genetic changes are not passed down to future generations. 1
To address the complexities of widespread adoption, Smith and Murthy proposed a framework involving five key factors for evaluating genomic interventions: disease severity, existing treatment options, durability of the effect, risks associated with delivery mechanisms, and the capacity for long-term monitoring. 1 The researchers emphasized that reliable systems for tracking long-term safety must be established before these technologies can be broadly recommended for common diseases. 1 The full findings were published in JAMA Internal Medicine, 2026, under DOI 10.1001/jamainternmed.2026.4690. 1
评论
还没有评论,欢迎留下第一条。